These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 19428875)

  • 1. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
    Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
    Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strain-specific humoral response to a polymorphic malaria vaccine.
    Flück C; Smith T; Beck HP; Irion A; Betuela I; Alpers MP; Anders R; Saul A; Genton B; Felger I
    Infect Immun; 2004 Nov; 72(11):6300-5. PubMed ID: 15501757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
    Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
    Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity.
    Flück C; Schöpflin S; Smith T; Genton B; Alpers MP; Beck HP; Felger I
    Infect Genet Evol; 2007 Jan; 7(1):44-51. PubMed ID: 16647307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization.
    Bermúdez A; Reyes C; Guzmán F; Vanegas M; Rosas J; Amador R; Rodríguez R; Patarroyo MA; Patarroyo ME
    Vaccine; 2007 May; 25(22):4487-501. PubMed ID: 17403557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice.
    Balam S; Jafarshad A; Servis C; Frank G; Reed S; Pink R; Druilhe P; Spertini F; Corradin G
    Vaccine; 2016 Mar; 34(13):1566-1574. PubMed ID: 26874325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic cross-reactivity between different alleles of the Plasmodium falciparum merozoite surface protein 2.
    Felger I; Steiger S; Hatz C; Smith T; Beck HP
    Parasite Immunol; 2003; 25(11-12):531-43. PubMed ID: 15053774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
    Patarroyo ME; Patarroyo MA
    Acc Chem Res; 2008 Mar; 41(3):377-86. PubMed ID: 18266328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.
    Genton B; Betuela I; Felger I; Al-Yaman F; Anders RF; Saul A; Rare L; Baisor M; Lorry K; Brown GV; Pye D; Irving DO; Smith TA; Beck HP; Alpers MP
    J Infect Dis; 2002 Mar; 185(6):820-7. PubMed ID: 11920300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa.
    Sirima SB; Nébié I; Ouédraogo A; Tiono AB; Konaté AT; Gansané A; Dermé AI; Diarra A; Ouédraogo A; Soulama I; Cuzzin-Ouattara N; Cousens S; Leroy O
    Vaccine; 2007 Mar; 25(14):2723-32. PubMed ID: 17280744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.
    Krishnarjuna B; Andrew D; MacRaild CA; Morales RA; Beeson JG; Anders RF; Richards JS; Norton RS
    Sci Rep; 2016 Feb; 6():20613. PubMed ID: 26865062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity.
    Bongfen SE; Ntsama PM; Offner S; Smith T; Felger I; Tanner M; Alonso P; Nebie I; Romero JF; Silvie O; Torgler R; Corradin G
    Vaccine; 2009 Jan; 27(2):328-35. PubMed ID: 18984024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmodium falciparum merozoite surface protein 2: epitope mapping and fine specificity of human antibody response against non-polymorphic domains.
    Balam S; Olugbile S; Servis C; Diakité M; D'Alessandro A; Frank G; Moret R; Nebie I; Tanner M; Felger I; Smith T; Kajava AV; Spertini F; Corradin G
    Malar J; 2014 Dec; 13():510. PubMed ID: 25526742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of three Pichia pastoris-expressed Plasmodium falciparum merozoite proteins as a combination vaccine against infection with blood-stage parasites.
    Zhang D; Pan W
    Infect Immun; 2005 Oct; 73(10):6530-6. PubMed ID: 16177327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
    Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
    Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
    Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
    N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and evaluation of a multistage combination vaccine against malaria.
    Zhang Q; Xue X; Qu L; Pan W
    Vaccine; 2007 Mar; 25(11):2112-9. PubMed ID: 17241708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against Plasmodium falciparum challenge induced in Aotus monkeys by liver-stage antigen-3-derived long synthetic peptides.
    Perlaza BL; Valencia AZ; Zapata C; Castellanos A; Sauzet JP; Blanc C; Cohen J; Arévalo-Herrera M; Corradin G; Herrera S; Druilhe P
    Eur J Immunol; 2008 Sep; 38(9):2610-5. PubMed ID: 18792413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa.
    Dobaño C; Doolan DL
    Mol Immunol; 2007 Apr; 44(11):3037-48. PubMed ID: 17303242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.